Compare like-for-like revenue
The reported-period revenue series records USD 1.24bn for the period ended September 30, 2026. That is 10.4% above the same reporting basis a year earlier.
—
—
—
Jazz Pharmaceuticals
—
—
Live Price
CIN RESEARCH · DATED EVIDENCE
Dated financial evidenceJazz Pharmaceuticals: revenue expanded; follow the cash evidence.
The reported-period revenue series records USD 1.24bn for the period ended September 30, 2026. That is 10.4% above the same reporting basis a year earlier. Cash and operating cash flow are available on a matching dated basis.
Latest financial observation 2026-09-30Last reported price 2026-11-06Research checked 2026-11-06 13:30 UTC
The check time records a research refresh. Each financial figure and price keeps its own reporting date.
Revenue and profitability are separate
The matching reported-period net loss is USD 483.4m. This is the reported result for 2026-09-30, not a future earnings estimate.
Put cash beside operating cash flow
Period-end cash was USD 2.04bn at 2026-09-30. The matching reported-period operating cash inflow was USD 506.1m. Later financing and cash movements are not established by this snapshot.
Reported financial evidence
| Measure | Reported value & unit | Period & interval | Evidence basis |
|---|---|---|---|
| Revenue | USD 1.24bnUnit: USD | Quarterly series | Dated financial series |
| Cost of revenue | USD 110.6mUnit: USD | Quarterly series | Dated financial series |
| Gross profit | USD 1.13bnUnit: USD | Quarterly series | Dated financial series |
| Operating income | USD -413.4mUnit: USD | Quarterly series | Dated financial series |
| EBITDA | USD -234.5mUnit: USD | Quarterly series | Dated financial series |
| Net income | USD -483.4mUnit: USD | Quarterly series | Dated financial series |
| Cash balance | USD 2.04bnUnit: USD | Balance at period end | Dated financial series |
| Total assets | USD 12bnUnit: USD | Balance at period end | Dated financial series |
| Total liabilities | USD 7.81bnUnit: USD | Balance at period end | Dated financial series |
| Shareholders’ equity | USD 4.19bnUnit: USD | Balance at period end | Dated financial series |
| Operating cash flow | USD 506.1mUnit: USD | Quarterly series | Dated financial series |
| Free cash flow | USD 489.9mUnit: USD | Quarterly series | Dated financial series |
A balance at period end is not income over a period. “Quarterly series” follows the available classification; the source disclosure establishes the actual reporting interval.
What changed against the prior year
Only the same measure, unit, reporting frequency and prior-year period end are compared. A reported change is not an investment rating.
Increased +10.4%
- 2025-09-30
- USD 1,126,107,000
- 2026-09-30
- USD 1,243,000,000
Decreased -57.1%
- 2025-09-30
- USD 257,760,000
- 2026-09-30
- USD 110,600,000
Increased +30.4%
- 2025-09-30
- USD 868,347,000
- 2026-09-30
- USD 1,132,400,000
Decreased -818.8%
- 2025-09-30
- USD 57,509,000
- 2026-09-30
- USD -413,400,000
Decreased -199.4%
- 2025-09-30
- USD 235,857,000
- 2026-09-30
- USD -234,500,000
Turned loss-making -292.3%
- 2025-09-30
- USD 251,412,000
- 2026-09-30
- USD -483,400,000
Increased +64.7%
- 2025-09-30
- USD 1,236,070,000
- 2026-09-30
- USD 2,036,400,000
Increased +5.6%
- 2025-09-30
- USD 11,356,485,000
- 2026-09-30
- USD 11,997,700,000
Increased +5.5%
- 2025-09-30
- USD 7,397,455,000
- 2026-09-30
- USD 7,805,900,000
Increased +5.9%
- 2025-09-30
- USD 3,959,030,000
- 2026-09-30
- USD 4,191,800,000
Increased +6.6%
- 2025-09-30
- USD 474,616,000
- 2026-09-30
- USD 506,100,000
Increased +6.6%
- 2025-09-30
- USD 459,441,000
- 2026-09-30
- USD 489,900,000
What to investigate next
- Resolve the conflicting financial observations against the primary report.
- Read the latest linked company disclosures and any reporting after the financial period.
- Check post-period financing, share issuance and changes in cash before drawing a current valuation conclusion.
Evidence boundaries
- Conflicting observations for the same concept, period and reporting basis are withheld.
- No dated primary company disclosures were supplied; absence in this feed is not a clean regulatory check.
- Interim frequency is provider-classified. Generic form labels are not treated as proof of an SEC filing or a three-month reporting duration.
- The earlier rating is not presented as a current conclusion. This report is rebuilt from dated evidence.
Independent evidence summary. No broker consensus, price target or investment rating is manufactured. Research standards →
Price History · USD
5 Years
Fundamentals
SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
CONTINUE YOUR RESEARCH